Teva still in pursuit of Mylan, raises guidance
This article was originally published in Scrip
Executive Summary
Teva has announced a solid first quarter on the back of a strong performance from its US generics business and has modestly raised its 2015 EPS by $0.05 to $5.05-$5.35.